Results 101 to 110 of about 9,215 (199)

Targeting Cancer Stem Cells with Radioimmunotherapy: The Case of the Ovarian Cancer Stemness-Associated Biomarker L1CAM

International Journal of Translational Medicine
Cancer stem cells (CSCs) are a dynamic population of tumor cells characterized by long-term self-renewal, high tumorigenicity, resistance to conventional therapies such as radio- and chemotherapy, and capacity to recapitulate the tumor heterogeneity ...
Tihomir Zh. Todorov, Roger Schibli, Martin Béhé, Jürgen Grünberg   +3 more
doaj   +1 more source

DNA-targeted radioimmunotherapy

Radioimmunotherapy is an experimental method of cancer treatment, involving the use of radioactive isotopes, which are targeted to tumour cells using specific molecules as carriers.

core  

Replication data for "A biomathematical model of tumor response to radioimmunotherapy with aPDL1 and aCTLA4"

Code and data supporting the paper "A biomathematical model of tumor response to radioimmunotherapy with aPDL1 and ...
López Pouso, Óscar, Pardo-Montero, Juan, Gómez-Caamaño, Antonio, Fenwick, John D, González-Crespo, Isabel   +4 more
core   +1 more source

Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin’s lymphoma

Exploration of Targeted Anti-tumor Therapy
Radioimmunotherapy (RIT) is a therapy that combines a radioactive nucleotide with a monoclonal antibody (mAb). RIT enhances the therapeutic effect of mAb and reduces toxicity compared with conventional treatment.
Hiroki Goto, Yoshioki Shiraishi, Seiji Okada   +2 more
doaj   +1 more source

Secondary antibodies as tools to improve tumor to non tumor ratio at radioimmunolocalisation and radioimmunotherapy

, 1996
One way of selectively improving the efficiency of radioimmunolocalization and radioimmunotherapy is to eliminate redundant, circulating, non-targeting radiolabeled antibodies after saturation of the target sites.
Hietala, Sven-Ola,, Nilsson, B, Ärlestig, L, Riklund, Katrine,, Ullén, Anders, Stigbrand, Torgny,   +5 more
core  

Radioimmunotherapy [PDF]

, 2020
openaire   +1 more source

Immune-sparing radiotherapy in solid tumors: radiation-induced lymphopenia, circulating immune-cell dose, and biomarker-guided optimization of radioimmunotherapy. [PDF]

J Cancer Res Clin Oncol
Yang S, Erdemutu E, Ren Y, Jia X, Ding Q, Yang C, Lin Y.   +6 more
europepmc   +1 more source

SIRT1 Inhibits T-cell Infiltration and Tertiary Lymphoid Structure Formation to Promote Radioimmunotherapy Resistance. [PDF]

Cancer Res
Shi Y, Wu ZF, Liu S, Wan T, Luo R, Liu H, Zeng Z, Li W, Liang Z, Xiong L, Luo S, Yuan Y, Huang L, Kang L.   +13 more
europepmc   +1 more source

Experimental radioimmunotherapy and effector mechanisms

, 2006
Radioimmunotherapy is becoming important as a new therapeutic strategy for treatment of tumour diseases. Lately monoclonal antibodies tagged with radionuclides have demonstrated encouraging results in treatment of hematological malignancies. The progress
Eriksson, David
core  

CD20-Targeted α-Radionuclides Synergize with Immune Checkpoint Inhibition to Treat Murine Lymphoma. [PDF]

J Nucl Med
O'Steen S, Lee SY, Comstock ML, Kehret AR, Lin Y, Hamlin DK, Dexter SL, Hippe DS, Gooley TA, Wilbur DS, Li Y, Walter RB, Till B, Orozco JJ, Green DJ.   +14 more
europepmc   +1 more source